Peter Lamprecht

List of Publications by Year
in descending order

95 papers	3,752 citations	147801 31 h-index	138484 58 g-index
107 all docs	107 docs citations	107 times ranked	4169 citing authors

#	Article	IF	Citations
1	Extracorporeal membrane oxygenation in ANCA-associated vasculitis. Autoimmunity Reviews, 2021, 20, 102702.	5.8	3
2	New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology, 2021, 60, 4868-4873.	1.9	23
3	Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Frontiers in Immunology, 2021, 12, 648408.	4.8	76
4	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
5	A patient with acute-onset hemorrhagic necroses and bullae of the legs. Rheumatology, 2021, 60, 5476-5477.	1.9	0
6	Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2-/-/IL2rg-/- Mice. Frontiers in Immunology, 2021, 12, 677970.	4.8	17
7	Granulomatous Inflammation in ANCA-Associated Vasculitis. International Journal of Molecular Sciences, 2021, 22, 6474.	4.1	23
8	The Joint Vasculitis Registry in German-speaking countries (GeVas) â€“ a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. BMC Rheumatology, 2021, 5, 40.	1.6	6
9	Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials, 2021, 22, 543.	1.6	31
10	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 182-183.	0.8	0
11	Expansion of CD161 expressing CD8+ single-positive and CD4+CD8+ double-positive PR3-specific T-cells in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2021, 39, 182-183.	0.8	0
12	Comment on: The nose is an organ too. Rheumatology, 2020, 59, e112-e113.	1.9	1
13	GPA-Induced Granulomatous Endocarditis Mimicking a Thrombotic Mitral Valve Stenosis. JACC: Case Reports, 2020, 2, 2151-2155.	0.6	2
14	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology, 2020, 59, 1185-1187.	1.9	4
15	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	12.8	160
16	Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1443-1444.	0.9	5
17	THU0316â€…PROTEINASE-3 REGULATING MICRO-RNA IN GRANULOMATOSIS WITH POLYANGIITIS. , 2019, , .		0
18	SP0183â€…DIAGNOSIS AND TREATMENT OF HCV RELATED VASCULITIS. , 2019, , .		0

#	Article	IF	Citations
19	SAT0021â€…ELEVATED NUMBERS OF C-TYPE LECTIN CD161 POSITIVE PR3-SPECIFIC T-CELLS IN GPA. , 2019, , .		0
20	AB0207â€…RECEPTOR EXPRESSION OF ANGIOTENSIN TYPE-1 AND 2 ARE DECREASED IN PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY ARTERIAL HYPERTENSION(PAH) AND CORRELATED WITH SEROLOGICAL LEVELS OF NT-PROBNP. , 2019, , .		0
21	Changes in the composition of the upper respiratory tract microbial community in granulomatosis with polyangiitis. Journal of Autoimmunity, 2019, 97, 29-39.	6.5	41
22	Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Stillâ€™s disease. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212608.	0.9	181
23	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
24	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nature Communications, 2018, 9, 5224.	12.8	116
25	Nomenklatur der kutanen Vaskulitiden â€“ deutschsprachige Definitionen des Dermatologischen Anhanges zur Chapel Hill Consensus Conference. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1425-1433.	0.8	15
26	Nomenclature of cutaneous vasculitides â€“ German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1425-1432.	0.8	18
27	In situ detection of PR3-ANCA+ B cells and alterations in the variable region of immunoglobulin genes support a role of inflamed tissue in the emergence of auto-reactivity in granulomatosis with polyangiitis. Journal of Autoimmunity, 2018, 93, 89-103.	6.5	19
28	Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides. Frontiers in Immunology, 2018, 9, 680.	4.8	76
29	Diagnosis of deficiency of adenosine deaminase 2 with early onset polyarteritis nodosa in an adult patient with a novel compound heterozygous CECR1 mutation. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 177.	0.8	4
30	Detection of anti-neutrophil cytoplasmic and antinuclear autoantibodies favouring misdiagnoses in 5 cases of Erdheim-Chester disease. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 176.	0.8	1
31	Circulating CD4+CD8+ double-positive T-cells display features of innate and adaptive immune function in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 93-98.	0.8	1
32	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of Hepatology, 2017, 66, 1282-1299.	3.7	73
33	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmunity Reviews, 2017, 16, 523-541.	5.8	87
34	Environmental factor and inflammation-driven alteration of the total peripheral T-cell compartment in granulomatosis with polyangiitis. Journal of Autoimmunity, 2017, 78, 79-91.	6.5	34
35	Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology, 2017, 8, 603.	4.8	377
36	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmunity Reviews, 2016, 15, 1145-1160.	5.8	87

#	Article	IF	Citations
37	Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics, 2016, 17, 367-374.	1.3	19
38	Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. Journal of Clinical Investigation, 2015, 125, 4107-4121.	8.2	101
39	Coâ€occurrence of autoantibodies in healthy blood donors. Experimental Dermatology, 2014, 23, 519-521.	2.9	32
40	Granulomatosis with Polyangiitis (Wegenerâ€™s Granulomatosis). , 2014, , 385-400.		2
41	L20. Memory T-cells in vasculitis. Presse Medicale, 2013, 42, 560-563.	1.9	3
42	VÎ´2 T cell deficiency in granulomatosis with polyangiitis (Wegener's granulomatosis). Clinical Immunology, 2013, 149, 65-72.	3.2	8
43	The Diagnosis and Treatment of Giant Cell Arteritis. Deutsches Ärzteblatt International, 2013, 110, 376-85; quiz 386.	0.9	100
44	Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by Mycophenolate Sodium: Figure 1.. Journal of Rheumatology, 2012, 39, 658-659.	2.0	6
45	Cartilage Destruction in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Is Mediated by Human Fibroblasts after Transplantation into Immunodeficient Mice. American Journal of Pathology, 2012, 180, 2144-2155.	3.8	30
46	Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis. Arthritis Research and Therapy, 2012, 14, R203.	3.5	15
47	Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener`s). Arthritis Research and Therapy, 2012, 14, R73.	3.5	8
48	Flow cytometric characterization of â€œearlyâ€•and â€œlate differentiatedâ€•Tâ€cells including PR3â€specific cells in granulomatosis with polyangiitis (Wegener's). Cytometry Part B - Clinical Cytometry, 2012, 82B, 173-175.	1.5	6
49	Longitudinal analysis of frequency and reactivity of epsteinâ€“barr virusâ€specific T lymphocytes and their association with intermittent viral reactivation. Journal of Medical Virology, 2012, 84, 119-131.	5.0	24
50	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 344-353.	6.4	182
51	Intra- and inter-rater reliability of endonasal activity estimation in granulomatosis with polyangiitis (WegenerÂ´s). Clinical and Experimental Rheumatology, 2012, 30, S22-8.	0.8	12
52	Increased frequency of IL-7 and IL-15 receptor alpha chain (CD127, CD215) co-expressing CD4(+) T cells in granulomatosis with polyangiitis (Wegener's). Clinical and Experimental Rheumatology, 2012, 30, S171.	0.8	1
53	T-helper cells as new players in ANCA-associated vasculitides. Arthritis Research and Therapy, 2011, 13, 236.	3.5	59
54	Local Expression of C-Reactive Protein Is Associated with Deteriorating Graft Function in Acute and Chronic Failure of Kidney Transplants. Nephron Clinical Practice, 2011, 117, 390-397.	2.3	5

#	Article	IF	Citations
55	Small Vessel Vasculitides. , 2011, , 389-403.		0
56	Distinct proteinase 3-induced cytokine patterns in WegenerÂ´s granulomatosis, Churg-Strauss syndrome, and healthy controls. Clinical and Experimental Rheumatology, 2011, 29, S57-62.	0.8	11
57	Antimicrobial peptides in nasal secretion and mucosa with respect to S. aureus colonisation in WegenerÂ´s granulomatosis. Clinical and Experimental Rheumatology, 2011, 29, S49-56.	0.8	10
58	Unclassified vasculitis. Clinical and Experimental Rheumatology, 2011, 29, S81-5.	0.8	2
59	Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Current Opinion in Rheumatology, 2010, 22, 43-48.	4.3	69
60	Genetic predisposition (NLRP3 V198M mutation) for IL-1â€“mediated inflammation in a patient with Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2010, 125, 500-502.	2.9	64
61	Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Clinical and Experimental Rheumatology, 2010, 28, 51-5.	0.8	54
62	Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study. Clinical and Experimental Rheumatology, 2010, 28, 67-71.	0.8	11
63	Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis. Clinical and Experimental Rheumatology, 2010, 28, 72-80.	0.8	16
64	Refractory Central Nervous System Vasculitis and Gastrocnemius Myalgia Syndrome in Crohn's Disease Successfully Treated with Anti-Tumor Necrosis Factor-Î± Antibody. Seminars in Arthritis and Rheumatism, 2009, 38, 337-347.	3.4	16
65	Granuloma formation in ANCAâ€associated vasculitides. Apmis, 2009, 117, 32-36.	2.0	31
66	Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides. Current Drug Discovery Technologies, 2009, 6, 241-251.	1.2	20
67	Anti-Citrullinated Protein-Peptide Antibodies in Rheumatoid Arthritis. Deutsches Ärzteblatt International, 2009, 106, 157-8.	0.9	4
68	Wegenerâ€™s Granulomatosis: The Current View. Clinical Reviews in Allergy and Immunology, 2008, 35, 19-21.	6.5	36
69	Clinical images: Saddlenose deformity caused by destructive granulomatous inflammation in Wegener's granulomatosis. Arthritis and Rheumatism, 2008, 58, 834-834.	6.7	4
70	Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clinical Immunology, 2008, 127, 144-150.	3.2	63
71	Antineutrophil cytoplasmic antibody-associated vasculitis: autoinflammation, autodestruction and autoimmunity â€“ key to new therapies. Trends in Immunology, 2008, 29, 587-588.	6.8	10
72	A little help from our friends: what an epidemiologic study teaches us about autoinflammation, granuloma and proteinase-3-specific antineutrophil cytoplasmic autoantibodies. Nephrology Dialysis Transplantation, 2008, 23, 3743-3745.	0.7	6

#	Article	IF	Citations
73	The low-penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis. Annals of the Rheumatic Diseases, 2007, 66, 1266-1267.	0.9	12
74	Biological therapies: new treatment options for ANCA-associated vasculitis?. Expert Opinion on Biological Therapy, 2007, 7, 521-533.	3.1	12
75	T cell alterations and lymphoid neogenesis favoring autoimmunity in Wegener's granulomatosis. Arthritis and Rheumatism, 2007, 56, 1725-1727.	6.7	16
76	Current State of Biologicals in the Management of Systemic Vasculitis. Annals of the New York Academy of Sciences, 2007, 1110, 261-270.	3.8	14
77	Diagnostic significance of ANCA in vasculitis. Nature Clinical Practice Rheumatology, 2006, 2, 174-175.	3.2	48
78	Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood, 2006, 107, 4440-4448.	1.4	100
79	Advances in the therapy of Wegener's granulomatosis. Current Opinion in Rheumatology, 2006, 18, 25-32.	4.3	50
80	Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 815a-816.	5.6	9
81	TNF-Î± inhibitors in systemic vasculitides and connective tissue diseases. Autoimmunity Reviews, 2005, 4, 28-34.	5.8	26
82	Small Vessel Vasculitides. , 2005, , 349-365.		0
83	TNF-Inhibitors in Wegenerâ€™s Granulomatosis. Kidney and Blood Pressure Research, 2005, 28, 62-62.	2.0	3
84	Wegener's Granulomatosis: A Pulmonary Perspective. Handbook of Systemic Autoimmune Diseases, 2004, 2, 63-94.	0.1	0
85	CD28- T cells display features of effector memory T cells in Wegener's granulomatosis. Kidney International, 2004, 65, 1113.	5.2	13
86	Wegener?s Granulomatosis. Herz, 2004, 29, 47-56.	1.1	79
87	A brief history of Wegener's granulomatosis: On limited, localized, and generalized forms of the disease: comment on the article by the Wegener's granulomatosis Etanercept Trial Research Group. Arthritis and Rheumatism, 2004, 50, 334-335.	6.7	14
88	Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. Journal of Autoimmunity, 2004, 22, 79-85.	6.5	36
89	Alterations in the phenotype of CMV-specific and total CD8+ T-cell populations in Wegenerâ€™s granulomatosis. Cellular Immunology, 2003, 224, 1-7.	3.0	14
90	Differences in CCR5 expression on peripheral blood CD4+CD28â¯ T-cells and in granulomatous lesions between localized and generalized Wegenerâ€™s granulomatosis. Clinical Immunology, 2003, 108, 1-7.	3.2	63

#	Article	IF	Citations
91	Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Research, 2003, 5, R25.	2.0	36
92	Peripheral Blood and Granuloma CD4+CD28â^' T Cells Are a Major Source of Interferon-Î³ and Tumor Necrosis Factor-Î± in Wegenerâ€™s Granulomatosis. American Journal of Pathology, 2002, 160, 1717-1724.	3.8	215
93	Small Vessel Vasculitides. , 2001, , 319-335.		0
94	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis and Rheumatism, 2000, 43, 226-231.	6.7	165
95	Immunological changes and prevention of disease progression through elotuzumab therapy in refractory IgG4-related sclerosing mesenteritis. Rheumatology, 0, , .	1.9	2